Please login to the form below

Not currently logged in
Email:
Password:

Weight-loss drugs under review

The US FDA is reviewing reports of serious liver injury in patients taking Roche's Xenical or GSK's over-the-counter version, alli

The US Food and Drug Administration (FDA) is reviewing reports of serious liver injury in patients taking Roche's Xenical or GlaxoSmithKline's (GSK) over-the-counter version, alli.

Thirty-two reports were received between 1999 and 2008 of serious liver injury in patients taking the weight-loss drug, known generically as orlistat. All but two of the cases occurred outside the US. Twenty-seven patients were hospitalised and six cases resulted in liver failure. The most commonly reported adverse effects included jaundice, weakness and stomach pain.

The FDA stated that it is reviewing additional information supplied by the manufacturers and that "no definite association between liver injury and orlistat has been established at this time." People who are taking the drug should continue to use it as directed, the agency added.

GSK said: "There is no evidence that alli causes liver damage which can stem from many causes. People who are overweight or obese are predisposed to liver-related disorders."

At time of press, no comment had been received from Roche.

25th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics